Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | ATP4A | P20648 | 1/20 | 0.43 |
| ▸ | ATP4B | P51164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168324 | 0.98 | CYP19A1 (0.59) | CYP19A1SIGMAR1FAAHMGLLGSK3A | |
| SCHEMBL3113486 | 0.95 | CYP19A1 (0.62) | CYP19A1SIGMAR1GSK3AGSK3BATP4A | |
| SCHEMBL6760657 | 0.87 | CYP19A1 (0.67) | CYP19A1MGLLGSK3AGSK3BATP4A | |
| SCHEMBL6582554 | 0.86 | HMOX1 (0.53) | CYP19A1MGLLATP4AATP4B | |
| SCHEMBL22398206 | 0.83 | CYP19A1 (0.41) | CYP19A1ATP4AATP4B | |
| SCHEMBL4856182 | 0.83 | MAOB (0.46) | CYP19A1SIGMAR1MAOA | |
| SCHEMBL2749688 | 0.83 | CYP19A1 (0.45) | CYP19A1MGLL | |
| SCHEMBL22398040 | 0.83 | HMOX1 (0.55) | CYP19A1 | |
| SCHEMBL6580252 | 0.81 | HMOX1 (0.54) | CYP19A1MGLLATP4AATP4B | |
| SCHEMBL22398032 | 0.80 | ERBB2 (0.45) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111886234-A | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2020-11-03 | — | — | CN | disclosed |
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
| US-6743924-B2 | EFFICIENT, HIGH YEILD SYNTHESIS OF TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| EP-1310491-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-1,2,3-TRIAZOLE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | ABL1, ROS1, ADH1A | CYP19A1 647/4885SIGMAR1 1646/4885FAAH 2660/4885 |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | ABL1, YES1, MAP3K1 | CYP19A1 686/4885SIGMAR1 1781/4885FAAH 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.